Gilead poaches senior BMS player for research biology division

Gilead has poached a senior player from Bristol-Myers Squibb (BMS) to serve as the Senior Vice President of its Research Biology division.

In his previous role, Dr Quigley served as Vice President and Head of BMS’ Tumour Microenvironment Modulation Thematic Research Centre and Site Head of the Redwood City, California location.

In that role, he was responsible for setting strategy for BMS’ oncology discovery portfolio and business development activities, overseeing target identification, validation and preclinical development of large and small molecule therapies.

Gilead has also promoted Dr Linda Higgins as Senior Vice President and Head of External Innovation.

She joined Gilead in 2010, leading a significant expansion of the company’s Biology organisation that included the establishment of Biologics and Biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.

Under Dr Higgins’ leadership, the Biology organisation supported the discovery and development of eight marketed products and the advancement of more than 30 compounds into development.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news